-transparent.png){kind=logo}
One hundred and seven untreated patients with acute myelogenous leukaemia (AML) were admitted to St Bartholomew's Hospital between 10 October 1970 and 31 January 1973. Before receiving drugs to induce remission they were allocated alternatively into 2 groups to decide their remission treatment-a group to receive chemotherapy alone and a group to receive the same chemotherapy with immunotherapy. The patients were then given induction chemotherapy and 45 of them attained complete remission. All patients in remission then received chemotherapy consisting of 5 days treatment every 28 days. Patients receiving immunotherapy were also given multiple weekly intradermal injections of irradiated stored AML cells and Glaxo B.C.G. using a Heaf gun. There were 19 patients in the group which received only chemotherapy during remission; 7 of these patients remain alive (median survival after attaining remission 303 days) and only 5 are still in their first remission (median remission length 188 days). Twenty-three patients were allocated to receive immunotherapy during remission in addition to chemotherapy and 16 remain alive (median 545 days) and 8 are in their first remission (median 312 days). The difference in survival of the two groups is significant with a P value of 0ยท003.
R L Powles, and
D Crowther, and
C J Bateman, and
M E Beard, and
T J McElwain, and
J Russell, and
T A Lister, and
J M Whitehouse, and
P F Wrigley, and
M Pike, and
P Alexander, and
G H Fairley
December 1977,
Lancet (London, England),
R L Powles, and
D Crowther, and
C J Bateman, and
M E Beard, and
T J McElwain, and
J Russell, and
T A Lister, and
J M Whitehouse, and
P F Wrigley, and
M Pike, and
P Alexander, and
G H Fairley
July 1974,
Irish journal of medical science,
R L Powles, and
D Crowther, and
C J Bateman, and
M E Beard, and
T J McElwain, and
J Russell, and
T A Lister, and
J M Whitehouse, and
P F Wrigley, and
M Pike, and
P Alexander, and
G H Fairley
August 1973,
The British journal of cancer. Supplement,
R L Powles, and
D Crowther, and
C J Bateman, and
M E Beard, and
T J McElwain, and
J Russell, and
T A Lister, and
J M Whitehouse, and
P F Wrigley, and
M Pike, and
P Alexander, and
G H Fairley
January 1974,
Johns Hopkins medical journal. Supplement,
R L Powles, and
D Crowther, and
C J Bateman, and
M E Beard, and
T J McElwain, and
J Russell, and
T A Lister, and
J M Whitehouse, and
P F Wrigley, and
M Pike, and
P Alexander, and
G H Fairley
September 1977,
British journal of haematology,
R L Powles, and
D Crowther, and
C J Bateman, and
M E Beard, and
T J McElwain, and
J Russell, and
T A Lister, and
J M Whitehouse, and
P F Wrigley, and
M Pike, and
P Alexander, and
G H Fairley
February 1977,
British journal of haematology,
R L Powles, and
D Crowther, and
C J Bateman, and
M E Beard, and
T J McElwain, and
J Russell, and
T A Lister, and
J M Whitehouse, and
P F Wrigley, and
M Pike, and
P Alexander, and
G H Fairley
March 1980,
British journal of cancer,
R L Powles, and
D Crowther, and
C J Bateman, and
M E Beard, and
T J McElwain, and
J Russell, and
T A Lister, and
J M Whitehouse, and
P F Wrigley, and
M Pike, and
P Alexander, and
G H Fairley
February 1998,
Critical reviews in oncology/hematology,
R L Powles, and
D Crowther, and
C J Bateman, and
M E Beard, and
T J McElwain, and
J Russell, and
T A Lister, and
J M Whitehouse, and
P F Wrigley, and
M Pike, and
P Alexander, and
G H Fairley
October 1975,
British journal of haematology,
R L Powles, and
D Crowther, and
C J Bateman, and
M E Beard, and
T J McElwain, and
J Russell, and
T A Lister, and
J M Whitehouse, and
P F Wrigley, and
M Pike, and
P Alexander, and
G H Fairley
July 1980,
British journal of haematology,
